Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Onconova Therapeutics stock

Learn how to easily invest in Onconova Therapeutics stock.

Onconova Therapeutics Inc is a biotechnology business based in the US. Onconova Therapeutics shares (ONTX) are listed on the NASDAQ and all prices are listed in US Dollars. Onconova Therapeutics employs 11 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Onconova Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ONTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Onconova Therapeutics stock price (NASDAQ: ONTX)

Use our graph to track the performance of ONTX stocks over time.

Onconova Therapeutics shares at a glance

Information last updated 2022-01-11.
Latest market close$2.22
52-week range$2.22 - $28.95
50-day moving average $3.00
200-day moving average $5.89
Wall St. target price$11.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.28

Buy Onconova Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$10 of crypto
Open an account with access to crypto
A platform built for all kinds of traders and all styles of trading
SoFi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in most equities.
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
Stocks, Options, ETFs
$0
$0 per year
Get a free stock valued up to $3500
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
$125 - $625
Open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Onconova Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Onconova Therapeutics price performance over time

Historical closes compared with the close of $2.22 from 2022-01-14

1 week (2022-01-06) -6.33%
1 month (2021-12-17) -17.47%
3 months (2021-10-13) N/A
6 months (2021-07-16) -56.64%
1 year (2021-01-15) 167.08%
2 years (2020-01-17) 441.46%
3 years (2019-01-17) 11.00%
5 years (2017-01-17) 2.7

Onconova Therapeutics financials

Revenue TTM $227,000
Gross profit TTM $231,000
Return on assets TTM -27.86%
Return on equity TTM -60.85%
Profit margin 0%
Book value $2.38
Market capitalisation $48.3 million

TTM: trailing 12 months

Onconova Therapeutics share dividends

We're not expecting Onconova Therapeutics to pay a dividend over the next 12 months.

Have Onconova Therapeutics's shares ever split?

Onconova Therapeutics's shares were split on a 1:15 basis on 20 May 2021. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Onconova Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Onconova Therapeutics shares which in turn could have impacted Onconova Therapeutics's share price.

Onconova Therapeutics share price volatility

Over the last 12 months, Onconova Therapeutics's shares have ranged in value from as little as $2.22 up to $28.95. A popular way to gauge a stock's volatility is its "beta".

ONTX.US volatility(beta: 1.67)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Onconova Therapeutics's is 1.669. This would suggest that Onconova Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Onconova Therapeutics overview

Onconova Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Its novel proprietary multi-kinase inhibitor ON 123300 to target CDK4/6 and other tyrosine kinases. The company's product candidate oral rigosertib, which is in Phase 1 study of rigosertib in combination with a PD-1 inhibitor for patients with progressive K-Ras mutated non-small cell lung cancer; and in Phase 1b/2 for recessive dystrophic epidermolysis bullosa. In addition, it is involved in preclinical work investigating rigosertib in COVID-19. The company has a license agreement with SymBio Pharmaceuticals Limited; and license, development, and commercialization agreement with Pint International SA.

Frequently asked questions

What percentage of Onconova Therapeutics is owned by insiders or institutions?
Currently 0.424% of Onconova Therapeutics shares are held by insiders and 17.466% by institutions.
How many people work for Onconova Therapeutics?
Latest data suggests 11 work at Onconova Therapeutics.
When does the fiscal year end for Onconova Therapeutics?
Onconova Therapeutics's fiscal year ends in December.
Where is Onconova Therapeutics based?
Onconova Therapeutics's address is: 375 Pheasant Run, Newtown, PA, United States, 18940
What is Onconova Therapeutics's ISIN number?
Onconova Therapeutics's international securities identification number is: US68232V8019
What is Onconova Therapeutics's CUSIP number?
Onconova Therapeutics's Committee on Uniform Securities Identification Procedures number is: 68232V108

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site